The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the clinical application for rapamycin was of course immune suppression so what made you think that you could actually use the same drug whose clinical indication was to suppress the immune system in a transplant patient to do the opposite which was to enhance the response to vaccine
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
of evidence that that many of the benefits that we see in mice from rapamycin occur because it tamps down on that sort of sterile inflammation that goes along with aging right the inappropriate activation of the immune system so in that sense you could think of it as an immune suppressant but but through mechanisms that i don't understand at all and i don't think anybody really understands um it seems to be more effective at targeting the bad the bad part of the aberrant immune response in an aged physiology which might be the reason why you're able to then have more of the good part and here i'm you know clearly showing my ignorance of immunology because i'm referring to it as bad and good right but i think in some ways that's it's useful to kind of think about it at that level because it's easier to appreciate that it's not you know not immune function isn't intrinsically good or bad right it it is and there are different types of immune responses and if you get the the wrong type of the immune immune response at the wrong time that's bad if you get the right type of immune response when you need it that's good right and and and i think in in the context of aging we just see a lot more of the bad and probably a decline in function of the good and and i don't know if rapamycin is affecting both of those but i think it's definitely affecting the bad and bringing it back down which might just be enough to allow the good to come back up where it's supposed to
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.